Biohaven is a clinical-stage biopharmaceutical company focused on therapies for patients with neurological and neuropsychiatric diseases. Co. has obtained drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia, and its research programs, develop therapies with indications in epilepsy, mood disorders, Obsessive-Compulsive Disorder, Spinocerebellar Ataxia, Spinal Muscular Atrophy and pain disorders. Co.'s neuroscience portfolio includes a range of pipeline of drug candidates modulating distinct nervous system targets, including Kv7 ion channels, glutamate receptors, myostatin, and transient receptor potential channels. The BHVN YTD return is shown above.
The YTD Return on the BHVN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether BHVN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BHVN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|